OLEMA PHARMACEUTICALS, INC. Investment Income, Nonoperating
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Investment Income, Nonoperating of $2.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNonoperating · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. investment income, nonoperating for the quarter ending 2026-06-30 was $1.22M, a 28.72% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. investment income, nonoperating for the quarter ending 2026-03-31 was $1.27M, a 39.41% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. investment income, nonoperating for the quarter ending 2025-09-30 was $1.32M, a 33.98% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. investment income, nonoperating for the quarter ending 2025-06-30 was $1.71M, a 21.82% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. investment income, nonoperating for fiscal 2024 was $8.18M, a 47.99% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. investment income, nonoperating for fiscal 2023 was $5.52M, a 601.91% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. investment income, nonoperating for fiscal 2022 was $787.00K.
| Period end | Investment Income, Nonoperating 3 month | Investment Income, Nonoperating 6 month | Investment Income, Nonoperating 9 month | Investment Income, Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.49M 10-Q · filed 2026-08-10 | ||
| 2026-03-31 | $1.27M 10-Q · filed 2026-05-12 | |||
| 2025-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.03M derived: sum of 2 quarters · filed 2026-08-10 | $5.13M 10-Q · filed 2025-11-10 | $6.76M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.81M 10-Q · filed 2026-08-10 | $5.44M derived: sum of 3 quarters · filed 2026-08-10 | $7.44M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.10M 10-Q · filed 2026-05-12 | $3.73M derived: sum of 2 quarters · filed 2026-05-12 | $5.73M derived: sum of 3 quarters · filed 2026-05-12 | $7.92M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $3.63M derived: sum of 2 quarters · filed 2025-11-10 | $5.82M derived: sum of 3 quarters · filed 2025-11-10 | $8.18M 10-K · filed 2025-03-18 |
| 2024-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.19M derived: sum of 2 quarters · filed 2025-11-10 | $6.55M 10-Q · filed 2025-11-10 | $8.82M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $4.55M 10-Q · filed 2025-08-11 | $6.82M derived: sum of 3 quarters · filed 2025-08-11 | $8.10M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $2.35M 10-Q · filed 2025-05-13 | $4.63M derived: sum of 2 quarters · filed 2025-05-13 | $5.91M derived: sum of 3 quarters · filed 2025-05-13 | $7.01M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $3.55M derived: sum of 2 quarters · filed 2025-03-18 | $4.66M derived: sum of 3 quarters · filed 2025-03-18 | $5.52M 10-K · filed 2025-03-18 |
| 2023-09-30 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.38M derived: sum of 2 quarters · filed 2024-11-12 | $3.25M 10-Q · filed 2024-11-12 | $3.82M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.97M 10-Q · filed 2024-08-06 | $2.54M derived: sum of 3 quarters · filed 2024-08-06 | $2.73M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $869.00K 10-Q · filed 2024-05-08 | $1.44M derived: sum of 2 quarters · filed 2024-05-08 | $1.63M derived: sum of 3 quarters · filed 2024-05-08 | |
| 2022-12-31 | $571.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $761.00K derived: sum of 2 quarters · filed 2024-03-11 | $787.00K 10-K · filed 2024-03-11 | |
| 2022-09-30 | $190.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $216.00K 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $26.00K 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |